Hepatocellular carcinoma: Towards personalized medicine

Cancer Science

Volumn 103, Issue 5, 2012, Pages 846-850

  Miki, Daiki ^a,b   Ochi, Hidenori ^a,b   Hayes, C Nelson ^a,b   Aikata, Hiroshi ^b   Chayama, Kazuaki ^a,b  

^a RIKEN   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; CANCER RISK; COFFEE; DIABETES MELLITUS; DIET; ETHNICITY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OBESITY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TOBACCO; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARCINOMA, HEPATOCELLULAR; CHINA; GENOME-WIDE ASSOCIATION STUDY; HEPACIVIRUS; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 84860252717     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02242.x     Document Type: Review

References (79)

1. Ozaki K, Ohnishi Y, Iida A et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32: 650-4.
2. Tsunoda T, Lathrop GM, Sekine A et al. Variation of gene-based SNPs and linkage disequilibrium patterns in the human genome. Hum Mol Genet 2004; 13: 1623-32.
3. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest 2008; 118: 1590-605.
4. International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-320.
5. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-64.
6. Hung SI, Chung WH, Jee SH et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
7. Kiyotani K, Mushiroda T, Sasa M et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008; 99: 995-9.
8. Chantarangsu S, Mushiroda T, Mahasirimongkol S et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin Infect Dis 2011; 53: 341-8.
9. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res 2009; 154: 277-87.
10. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
11. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
12. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
13. Fellay J, Thompson AJ, Ge D et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-8.
14. Ochi H, Maekawa T, Abe H et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy. Gastroenterology 2010; 139: 1190-7.
15. Chayama K, Hayes CN, Yoshioka K et al. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C. Hepatol Res 2010; 40: 1155-67.
16. Afdhal NH, McHutchison JG, Zeuzem S et al. Hepatitis C pharmacogenetics. Hepatology 2011; 53: 336-45.
17. Hayes CN, Kobayashi M, Akuta N et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011; 60: 261-7.
18. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-58.
19. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-63.
20. Barrera JM, Bruguera M, Ercilla MG et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21: 639-44.
21. Ikeda K, Saitoh S, Suzuki Y et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis. J Hepatol 1998; 28: 930-8.
22. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma. Ann Intern Med 1999; 131: 174-81.
23. Kiyosawa K, Umemura T, Ichijo T et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127: S17-26.
24. Ohishi W, Fujiwara S, Cologne JB et al. Risk factors for hepatocellular carcinoma in a Japanese population. Cancer Epidemiol Biomarkers Prev 2008; 17: 846-54.
25. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009; 24: 346-53.
26. Yang HI, Yeh SH, Chen PJ et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-43.
27. Wang Y, Kato N, Hoshida Y et al. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 2003; 37: 65-71.
28. Tanaka Y, Furuta T, Suzuki S et al. Impact of interleukin-1beta genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan. J Infect Dis 2003; 187: 1822-5.
29. Sakamoto T, Higaki Y, Hara M et al. Interaction between interleukin-1beta -31T/C gene polymorphism and drinking and smoking habits on the risk of hepatocellular carcinoma among Japanese. Cancer Lett 2008; 271: 98-104.
30. Okamoto K, Ishida C, Ikebuchi Y et al. The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Intern Med 2010; 49: 887-95.
31. Dharel N, Kato N, Muroyama R et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 2006; 12: 4867-71.
32. Wang Y, Kato N, Hoshida Y et al. UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in Japanese patients with hepatitis C virus infection. Clin Cancer Res 2004; 10: 2441-6.
33. Chen CC, Yang SY, Liu CJ et al. Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol 2005; 34: 1310-8.
34. Migita K, Maeda Y, Abiru S et al. Polymorphisms of interleukin-1beta in Japanese patients with hepatitis B virus infection. J Hepatol 2007; 46: 381-6.
35. Yoon YJ, Chang HY, Ahn SH et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008; 29: 1192-6.
36. Kong SY, Ki CS, Yoo BC, Kim JW. UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers. Cancer Sci 2008; 99: 340-4.
37. Ezzikouri S, El Feydi AE, El Kihal L et al. Prevalence of common HFE and SERPINA1 mutations in patients with hepatocellular carcinoma in a Moroccan population. Arch Med Res 2008; 39: 236-41.
38. Ezzikouri S, El Feydi AE, Chafik A et al. Genetic polymorphism in the manganese superoxide dismutase gene is associated with an increased risk for hepatocellular carcinoma in HCV-infected Moroccan patients. Mutat Res 2008; 649: 1-6.
39. Nahon P, Sutton A, Pessayre D et al. Manganese superoxide dismutase dimorphism and iron overload, hepatocellular carcinoma, and death in hepatitis C virus-infected patients. Clin Gastroenterol Hepatol 2007; 5: 630-5.
40. McIlroy D, Théodorou I, Ratziu V et al. FAS promoter polymorphisms correlate with activity grade in hepatitis C patients. Eur J Gastroenterol Hepatol 2005; 17: 1081-8.
41. Li CZ, Kato N, Chang JH et al. Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. Liver Int 2009; 29: 1413-21.
42. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010; 363: 166-76.
43. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C. Hepatology 1999; 29: 1124-30.
44. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
45. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001; 358: 958-65.
46. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of Hepatitis C. Hepatology 2009; 49: 1335-74.
47. Enomoto N, Sakuma I, Asahina Y et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995; 96: 224-30.
48. Akuta N, Suzuki F, Kawamura Y et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Hepatol 2007; 46: 403-10.
49. Everson GT, Hoefs JC, Seeff LB et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C. Hepatology 2006; 44: 1675-84.
50. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64.
51. Romero-Gómez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
52. Tsukada H, Ochi H, Maekawa T et al. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology 2009; 136: 1796-805.
53. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
54. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
55. Chayama K, Takahashi S, Toyota J et al. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders. Hepatology 2012; 55: 742-8.
56. Suzuki F, Suzuki Y, Akuta N et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011; 53: 415-21.
57. Chayama K, Hayes CN, Abe H et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204: 84-93.
58. Kamatani Y, Wattanapokayakit S, Ochi H et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591-5.
59. Guo X, Zhang Y, Li J et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology 2011; 53: 422-8.
60. Zhang H, Zhai Y, Hu Z et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010; 42: 755-8.
61. Tsuge M, Takahashi S, Hiraga N et al. Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice. J Infect Dis 2011; 204: 224-8.
62. Tsuge M, Fujimoto Y, Hiraga N et al. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. PLoS ONE 2011; 6: e23856.
63. Ura S, Honda M, Yamashita T et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49: 1098-112.
64. Kumar V, Kato N, Urabe Y et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011; 43: 455-8.
65. Miki D, Ochi H, Hayes CN et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 2011; 43: 797-800.
66. Ohishi W, Kitamoto M, Aikata H et al. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand J Gastroenterol 2003; 38: 894-900.
67. Miki D, Aikata H, Uka K et al. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol 2008; 43: 550-7.
68. Taura N, Hamasaki K, Nakao K et al. Aging of patients with hepatitis C virus-associated hepatocellular carcinoma. Oncol Rep 2006; 16: 837-43.
69. Jinushi M, Takehara T, Tatsumi T et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003; 104: 354-61.
70. Kharrat A, Millevoi S, Baraldi E, Ponting CP, Bork P, Pastore A. Conformational stability studies of the pleckstrin DEP domain. Biochim Biophys Acta 1998; 1385: 157-64.
71. Arii S, Sata M, Sakamoto M et al. Hepatol Res. Management of hepatocellular carcinoma. Hepatol Res 2010; 40: 667-85.
72. Kudo M, Izumi N, Kokudo N et al. Management of hepatocellular carcinoma in Japan. Dig Dis 2011; 29: 339-64.
73. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. J Hepatol 2001; 35: 421-30.
74. Benson AB 3rd, Abrams TA, Ben-Josef E et al. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009; 7: 350-91.
75. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-42.
76. Kawaoka T, Aikata H, Katamura Y et al. Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 1219-25.
77. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410-26.
78. Totoki Y, Tatsuno K, Yamamoto S et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 2011; 43: 464-9.
79. Li M, Zhao H, Zhang X et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011; 43: 828-9.